ACA subsidies extended, PBM profits capped, broker fraud crackdown

What it does

This bill extends and expands the Affordable Care Act's premium tax credit (which helps people afford health insurance) through 2026 and beyond, allowing more middle-income people to qualify. It also adds fraud-prevention measures for health insurance brokers and agents, removes deceased people from exchange plans, extends the 2026 open enrollment period, and imposes new transparency and accountability rules on pharmacy benefit managers (PBMs) to prevent them from profiting at the expense of Medicare drug plans and patients.

Why we flagged it

The bill's core mechanisms are (1) extending and expanding premium tax credits to make insurance more affordable for middle-income households, and (2) adding enforcement and transparency rules to prevent fraud by brokers and PBMs. Both are consumer-protection and affordability measures, not industry giveaways.

What the text implies

• The 2026 premium percentage table (0% for households up to 150% of poverty line, scaling to 10% for 900–1000%) may create a cliff effect for households just above 1000% of poverty line, who lose all subsidy eligibility—potential coverage loss for near-threshold families.
• PBM transparency requirements (detailed drug-by-drug reporting, affiliate markup disclosure, audit rights) may increase administrative costs for PBMs, which could be passed to plan sponsors or enrollees if not offset by savings from reduced hidden profits.
• The extended 2026 open enrollment period (Nov 1, 2025–Mar 19, 2026) is unusually long and may increase administrative burden on exchanges and insurers, though it improves access for late enrollees.
• Removal of deceased individuals from plans via Death Master File checks may lag real-world deaths by 90+ days, creating a window for improper claims or premium collection on behalf of deceased enrollees.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands subsidies for middle-income people buying health insurance, making coverage more affordable. It also strengthens guardrails against fraud by brokers and agents, removes deceased people from plans (preventing improper claims), and constrains pharmacy benefit managers' ability to profit from hidden markups—all of which protect consumers and plan integrity.

Who stands to gain

• Individuals earning 150–1000% of federal poverty line (expanded subsidy eligibility)
• Health insurance plan sponsors (reduced fraud losses, better PBM cost control)
• Pharmacies (potential benefit from reduced PBM overreach and affiliate-pharmacy discrimination)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Health Insurance Exchanges, Pharmacy Benefit Managers (PBMs), PDP Sponsors (prescription drug plan sponsors), Medicare Advantage organizations, Insurance brokers and agents, Drug manufacturers, Pharmacies, Internal Revenue Service (IRS), Department of Health and Human Services (HHS), Inspector General of HHS, Comptroller General (GAO) — and 1 more

Where it stands

38 cosponsors: 23 Democrats, 14 Republicans, 1 Independents.

• Dec 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 10, 2025 — Referred to House Committee on Rules and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $7,480,000 in lobbying spend. A filing names 30 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Jennifer Kiggans, the sponsor, reported $1,313,089 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• CVS Health (and Subsidiaries) — $3,570,000 on 1 filing
• National Association of Chain Drug Stores — $290,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.